CODX Co-diagnostics
- 1.200
- +0.010+0.84%
- 1.170
- -0.030-2.50%
Co-diagnostics News
Co-Diagnostics, Inc. Announces First Quarter 2024 Earnings Release Date and Webcast
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic...
Co-Diagnostics, Inc. Appoints Richard Abbott As President, Concurrent With The Co Naming David Nielsen To Be Its Chief Operations Officer
Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that
Co-Diagnostics Names David Nielsen as Chief Ops Officer and Christopher Thurston as Chief Technology Officer >CODX
Co-Diagnostics Names David Nielsen as Chief Ops Officer and Christopher Thurston as Chief Technology Officer >CODX
Press Release: Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions
Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions PR Newswire SALT LAKE CITY, April 4, 2024 SALT LAKE CITY, April 4, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (
Co-Diagnostics: Richard Abbott Appointed as Pres >CODX
Co-Diagnostics: Richard Abbott Appointed as Pres >CODX
Peering Into Co-Diagnostics's Recent Short Interest
Co-Diagnostics's (NYSE:CODX) short percent of float has risen 12.61% since its last report. The company recently reported that it has 381 thousand shares sold short, which is 1.25% of all regular shar
Co-Diagnostics, Inc. CEO Delivers Manufacturing and Commercialization Update in Conference Keynote Address
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development...
Co-Diagnostics, Inc. CEO to Deliver Keynote Address at MarketsandMarkets 2024 in London, England
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development...
We Think Co-Diagnostics (NASDAQ:CODX) Needs To Drive Business Growth Carefully
Co-Diagnostics Full Year 2023 Earnings: Misses Expectations
Co-Diagnostics Inc Welcomes Richard Abbott as New President
Co-Diagnostics Price Target Cut to $2.50/Share From $3.00 by HC Wainwright & Co.
Co-Diagnostics Price Target Cut to $2.50/Share From $3.00 by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $2.5
Maintaining Hold on Co-Diagnostics Amid Revenue Decline and Potential EUA Boost
Earnings Call Summary | Co-diagnostics(CODX.US) Q4 2023 Earnings Conference
The following is a summary of the Co-Diagnostics, Inc. (CODX) Q4 2023 Earnings Call Transcript:Financial Performance:Co-Diagnostics reported a total revenue decrease to $6.8 million in 2023, compared
Co-Diagnostics: Q4 Earnings Insights
Co-Diagnostics (NASDAQ:CODX) reported its Q4 earnings results on Thursday, March 14, 2024 at 04:01 PM.Here's what investors need to know about the announcement.EarningsCo-Diagnostics missed estimated
Express News | Co-Diagnostics Q4 2023 GAAP EPS $(0.50) Misses $(0.20) Estimate, Sales $3.555M Miss $3.625M Estimate
Press Release: Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results
Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results PR Newswire SALT LAKE CITY, March 14, 2024 SALT LAKE CITY, March 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecu
Notable Earnings After Thursday's Close
Earnings Preview: Co-Diagnostics
Co-Diagnostics (NASDAQ:CODX) is set to give its latest quarterly earnings report on Thursday, 2024-03-14. Here's what investors need to know before the announcement.Analysts estimate that Co-Diagnosti
Analysis
Price Target
No Data
